Health Care

Capricor Therapeutics pursues breakthrough therapies for Duchenne muscular dystrophy, navigating biotech volatility while driving innovation and patient hope.

Explore how Stryker Corp’s new CEO, amid 2026 policy uncertainty and cyber threats, faces short‑term pain yet aims for 2027 growth in robotics and AI‑driven devices.

GSK invests $800 million in a new Pennsylvania hub and partners with AI firm Chai Discovery, boosting U.S. manufacturing, jobs, and drug‑discovery speed.

Abivax SA leads biotech innovation with Phase II trials for HIV, hepatitis B, and emerging virus therapies, boosting global health outcomes.

Satellos Bioscience, a Toronto‑based biotech, is pioneering skeletal muscle regeneration drugs that boost the body’s own repair, aiming to transform treatment for severe muscle disorders.

Explore Zentalis Pharmaceuticals’ journey to develop groundbreaking small‑molecule cancer drugs, its volatile Nasdaq performance, and what it means for investors and patients alike.

Vaxcyte’s $11B equity‑debt offering fuels its vaccine innovation push—boosting R&D and global health impact with robust financial backing.

Vanda Pharmaceuticals’ 13G/A filing shows Millennium entities hold ~7% of shares, yet no control intent—still focused on CNS drug development.

Argenx’s celiac win vs. Sjögren’s setback: how a Phase II breakthrough and a Phase III failure reshape its stock, valuation, and investor outlook.

Phio Pharmaceuticals advances cancer immunotherapy, tackling R&D and market volatility while targeting personalized treatments—discover its biotech prospects.